Related references
Note: Only part of the references are listed.Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study
M. J. Cork et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents
Amelia Licari et al.
PEDIATRIC DRUGS (2020)
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
Amy S. Paller et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: partII
A. Wollenberg et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I
A. Wollenberg et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
A starch, glycyrretinic, zinc oxide and bisabolol based cream in the treatment of chronic mild-to-moderate atopic dermatitis in children: a three-center, assessor blinded trial
Amelia Licari et al.
MINERVA PEDIATRICA (2017)
Share Paper
